Short Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Declines By 46.7%

Key Points

• Short interest in Telix Pharmaceuticals decreased by 46.7% in September, from 222,500 shares to 118,600 shares.
• Hedge funds have recently increased their positions in Telix, with significant investments from multiple firms totaling over $4 million.
• Several analysts have issued ratings, with a consensus target price of $21.00, reflecting a mix of Buy, Hold, and Sell ratings for the stock.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 118,600 shares, a decline of 46.7% from the August 31st total of 222,500 shares. Based on an average trading volume of 153,600 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 153,600 shares, the short-interest ratio is presently 0.8 days.

Institutional Trading of Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in TLX. Private Advisor Group LLC bought a new stake in shares of Telix Pharmaceuticals in the first quarter worth $170,000. ABC Arbitrage SA acquired a new position in shares of Telix Pharmaceuticals during the 1st quarter worth approximately $451,000. Blair William & Co. IL acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $297,000. Finally, Pier Capital LLC acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $3,037,000.

Wall Street Analysts Forecast Growth

TLX has been the subject of several research analyst reports. UBS Group decreased their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, September 23rd. William Blair reissued an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Citigroup initiated coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a "buy" rating and a $22.00 price target for the company. HC Wainwright decreased their price target on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, September 10th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Saturday, September 27th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Telix Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Up 0.6%

Shares of TLX stock traded up $0.06 on Friday, hitting $10.28. 131,334 shares of the stock were exchanged, compared to its average volume of 218,140. The business has a 50-day moving average of $10.82 and a 200 day moving average of $14.63. Telix Pharmaceuticals has a fifty-two week low of $8.93 and a fifty-two week high of $30.36.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.